Increasing transparency on generic drug cost data could save $4 billion

Making actual generic drug acquisition costs available to third-party payers would empower health plans to negotiate lower rates and essentially level the playing field in a pharmaceutical supply chain that’s shrouded in secrecy, according to a new paper.

Making actual generic drug acquisition costs available to third-party payers would empower health plans to negotiate lower rates